News >

FDA Approves Abiraterone for High-Risk Prostate Cancer

Silas Inman @silasinman
Published: Thursday, Feb 08, 2018

Karim Fizazi, MD, PhD
Karim Fizazi, MD, PhD
The FDA has approved abiraterone acetate (Zytiga) in combination with prednisone for patients with metastatic high-risk castration-sensitive prostate cancer, based on findings from the phase III LATITUDE trial.1

The approval, which was announced by the company developing the therapy, Janssen Biotech, was based on a 38% reduction in the risk of death with the addition of abiraterone acetate and prednisone to ADT compared with ADT alone. After a median follow-up of 30.4 months, median overall survival (OS) was not yet reached with abiraterone acetate versus 34.7 months with placebo for patients with high-risk metastatic, castration-sensitive prostate cancer (HR, 0.62; 95% CI, 0.51-0.76; P <.001).

“LATITUDE was a large global trial which produced impressive and clinically significant results in overall survival,” lead investigator of the study Karim Fizazi, MD, PhD, Head of the Medical Oncology Department at Institute Gustave Roussy, Villejuif, France, said in a statement. “With today’s approval, abiraterone acetate plus prednisone could become a standard of care for patients with metastatic high-risk castration-sensitive prostate cancer.”

In the LATITUDE trial, 1199 newly diagnosed patients with high-risk metastatic prostate cancer were randomized to abiraterone acetate, prednisone, and ADT (n = 597) or ADT and placebo (n = 602). Abiraterone acetate was administered at 1000 mg daily, prednisone was given at 5 mg daily, and ADT consisted of a gonadotropin-releasing hormone (GnRH) analog. Patients had not received prior ADT and had at least 2 of 3 risk factors: Gleason score greater ≥8, measurable visceral metastases, or ≥3 bone lesions.

In each group, approximately 20% of patients were ≥75 years of age, with a median age around 68 years. The Gleason score at diagnosis was ≥8 for nearly all men enrolled (98%) and nearly all enrolled had ≥3 sites of bone metastases (98%). The baseline pain score was ≥4 for just over a quarter of men in the trial, and the majority had a pain score of 0 or 1 (50%).

The median radiographic progression-free survival with abiraterone acetate was 33.0 months compared with 14.8 months for ADT alone, representing a 53% reduction in the risk of progression or death (HR, 0.47; 95% CI, 0.39-0.55; P <.001). The OS rate at 3 years was 66% in the abiraterone acetate group versus 49% with ADT.

The time to pain progression was reduced by 31% with abiraterone acetate versus ADT (HR, 0.695; 95% CI, 0.583-0.829; P <.0001). Additionally, the risk of developing a skeletal-related event was 30% lower with abiraterone acetate versus ADT (HR, 0.703; 95% CI, 0.539-0.916; P = .0086). The risk of starting chemotherapy was reduced by 56% with abiraterone acetate versus ADT alone (HR, 0.443; 95% CI, 0.349-0.561; P <.0001).

Overall, 63% of men in the abiraterone acetate group experienced a grade 3/4 adverse event (AE) compared with 48% of those in the placebo arm. The most common grade 3/4 AEs with abiraterone acetate versus placebo, respectively, were hypertension (20.3% vs 10.0%); hypokalemia (10.4% vs 1.3%); elevated alanine aminotransferase (5.5% vs 1.3%), and elevated aspartate aminotransferase (4.4% vs 1.5%).

Serious AEs were experienced by 28% versus 24% of men in the abiraterone acetate group and placebo arm, respectively. AEs led to treatment discontinuation for 12% of men in the investigational group versus 10% in the placebo arm, and AEs led to death for 5% and 4% of men, respectively.

In a further analysis of patient-reported outcomes,2 there was a delay in degradation of health-related quality of life (HrQOL) with abiraterone acetate versus ADT alone. This equated to a 15% reduction in the risk of HrQOL degradation with the addition of abiraterone acetate (HR, 0.85; 95% CI, 0.74-0.99; P = .0322). Moreover, the time to worst fatigue intensity progression was delayed by 35% (HR, 0.65; 95% CI, 0.53-0.81; P = .0001).

“Today’s approval marks an important step in addressing the unmet needs of patients with metastatic high-risk castration-sensitive prostate cancer by providing an option that has demonstrated improvement in overall survival,” Andree Amelsberg, MD, vice president of Oncology Medical Affairs at Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, said in a statement. “This milestone is an exciting turning point for researchers and clinicians, and most importantly, for patients suffering from this disease and their families who now have an important additional therapeutic option.”

Abiraterone acetate was first approved in 2011 in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer following chemotherapy. It has since gained approval earlier in the treatment paradigm for use prior to chemotherapy.
References:
  1. Fizazi K, Tran N, Fein LE, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377:352-360.
  2. Chi K, Protheroe A, Rodrigues Antolin A, et al. Benefits of Abiraterone Acetate Plus Prednisone (AA+P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO). Presented at: 2017 ESMO Congress; Madrid, Spain; September 8-12, 2017. Abstract 783O.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x